Clinical relevance of RORγ positive and negative subsets of CD161+CD4+ T cells in primary Sjögren's syndrome

Rheumatology (United Kingdom)

Volumn 56, Issue 2, 2017, Pages 303-312

  Zhao, Linlin ^a   Nocturne, Gaetane ^b,c,d   Haskett, Scott ^a   Boudaoud, Saida ^b,c   Lazure, Thierry ^b,c,d   Le Pajolec, Christine ^d   Mariette, Xavier ^b,c,d   Mingueneau, Michael ^a   Banerjee, Daliya ^a  

^a BIOGEN   (United States)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSERM U1184   (France)

^d BICÊTRE HOSPITAL   (France)

Author keywords

CD161; Primary Sj gren's syndrome; ROR gamma; Salivary gland biopsy; Th17

Indexed keywords

CD161 ANTIGEN; CD4 ANTIGEN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; LA ANTIBODY; METHOTREXATE; RETINOID RELATED ORPHAN RECEPTOR GAMMA; RHESUS D ANTIGEN; RO ANTIBODY; STEROID; ANTINUCLEAR ANTIBODY; HLA DR ANTIGEN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY B; RORC PROTEIN, HUMAN; SS-A ANTIBODIES; SS-B ANTIBODIES;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CD161+ CD4+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HLA SYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SALIVARY GLAND; SALIVARY GLAND BIOPSY; SJOEGREN SYNDROME; T LYMPHOCYTE ACTIVATION; TH17 CELL; AGED; CASE CONTROL STUDY; HUMORAL IMMUNITY; HYPERGAMMAGLOBULINEMIA; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MINOR SALIVA GLAND; MONONUCLEAR CELL; T LYMPHOCYTE SUBPOPULATION;

ADULT; AGED; ANTIBODIES, ANTINUCLEAR; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; HLA-DR ANTIGENS; HUMANS; HYPERGAMMAGLOBULINEMIA; IMMUNITY, HUMORAL; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY B; NUCLEAR RECEPTOR SUBFAMILY 1, GROUP F, MEMBER 3; SALIVARY GLANDS, MINOR; SJOGREN'S SYNDROME; T-LYMPHOCYTE SUBSETS; TH17 CELLS;

EID: 85014294601     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kew360     Document Type: Article

References (47)

1. Nocturne G, Mariette X. Advances in understanding the pathogenesis of primary Sjögren's syndrome. Nat Rev Rheumatol 2013;9:544-56.
2. Mingueneau M, Boudaoud S, Haskett S et al. Cytometry by time-of-flight immunophenotyping identifies a blood Sjögren's signature correlating with disease activity and glandular inflammation. J Allergy Clin Immunol 2016;137:1809-21.e12.
3. Maehara T, Moriyama M, Hayashida JN et al. Selective localization of T helper subsets in labial salivary glands from primary Sjögren's syndrome patients. Clin Exp Immunol 2012;169:89-99.
4. Moriyama M, Hayashida JN, Toyoshima T et al. Cytokine/ chemokine profiles contribute to understanding the pathogenesis and diagnosis of primary Sjögren's syndrome. Clin Exp Immunol 2012;169:17-26.
5. Kolkowski EC, Reth P, Pelusa F et al. Th1 predominance and perforin expression in minor salivary glands from patients with primary Sjögren's syndrome. J Autoimmun 1999;13:155-62.
6. Mitsias DI, Tzioufas AG, Veiopoulou C et al. The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjögren's syndrome. Clin Exp Immunol 2002;128:562-8.
7. Ohyama Y, Nakamura S, Matsuzaki G et al. Cytokine messenger RNA expression in the labial salivary glands of patients with Sjögren's syndrome. Arthritis Rheum 1996;39:1376-84.
8. Mieliauskaite D, Dumalakiene I, Rugiene R, Mackiewicz Z. Expression of IL-17, IL-23 and their receptors in minor salivary glands of patients with primary Sjögren's syndrome. Clin Dev Immunol 2012;2012:187258.
9. Sakai A, Sugawara Y, Kuroishi T, Sasano T, Sugawara S. Identification of IL-18 and Th17 cells in salivary glands of patients with Sjögren's syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18. J Immunol 2008;181:2898-906.
10. Niederreiter L, Adolph TE, Kaser A. Anti-IL-12/23 in Crohn's disease: bench and bedside. Current Drug Targets 2013;14:1379-84.
11. Hueber W, Patel DD, Dryja T et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010; 2:52ra72.
12. Leonardi C, Matheson R, Zachariae C et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366: 1190-9.
13. Papp KA, Leonardi C, Menter A et al. Brodalumab, an antiinterleukin-17-receptor antibody for psoriasis. N Engl J Med 2012;366:1181-9.
14. Poddubnyy D, Hermann KG, Callhoff J et al. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis 2014;73:817-23.
15. Ciofani M, Madar A, Galan C et al. A validated regulatory network for Th17 cell specification. Cell 2012;151:289-303.
16. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 2009;27:485-517.
17. Iizuka M, Tsuboi H, Matsuo N et al. A crucial role of RORgt in the development of spontaneous Sialadenitis-like Sjögren's syndrome. J Immunol 2015;194:56-67.
18. Nguyen CQ, Hu MH, Li Y, Stewart C, Peck AB. Salivary gland tissue expression of interleukin-23 and interleukin-
19. in Sjögren's syndrome: findings in humans and mice. Arthritis Rheum 2008;58:734-43.
20. Katsifis GE, Rekka S, Moutsopoulos NM, Pillemer S, Wahl SM. Systemic and local interleukin-17 and linked cytokines associated with Sjögren's syndrome immunopathogenesis. Am J Pathol 2009;175:1167-77.
21. Alunno A, Carubbi F, Bartoloni E et al. Unmasking the pathogenic role of IL-17 axis in primary Sjögren's syndrome: a new era for therapeutic targeting? Autoimmun Rev 2014;13:1167-73.
22. Dusseaux M, Martin E, Serriari N et al. Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. Blood 2011;117:1250-9.
23. Maggi L, Santarlasci V, Capone M et al. CD161 is a marker of all human IL-17-producing T-cell subsets and is induced by RORC. Eur J Immunol 2010;40:2174-81.
24. Fergusson JR, Fleming VM, Klenerman P. CD161-expressing human T cells. Front Immunol 2011;2:36.
25. Fergusson JR, Smith KE, Fleming VM et al. CD161 defines a transcriptional and functional phenotype across distinct human T cell lineages. Cell Rep 2014;9:1075-88.
26. Miao J, Zhang K, Lv M et al. Circulating Th17 and Th1 cells expressing CD161 are associated with disease activity in rheumatoid arthritis. Scand J Rheumatol 2014;43:194-201.
27. +T cells bear pathogenetic potential in multiple sclerosis. Brain 2011;134:542-54.
28. + T cell precursor. J Exp Med 2008;205: 1903-16.
29. Kleinschek MA, Boniface K, Sadekova S et al. Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J Exp Med 2009;206:525-34.
30. Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjects. Arthritis Rheum 2005;52:1534-44.
31. Banerjee D, Zhao L, Wu L et al. Small molecule mediated inhibition of RORg-dependent gene expression and autoimmune disease pathology in vivo. Immunology 2016;147:399-413.
32. + T cells capable of producing proinflammatory cytokines. Blood 2013;121: 2647-58.
33. + T cells in the synovial fluid of patients with juvenile idiopathic arthritis. Arthritis Rheum 2008;63:2504-15.
34. Peters A, Pitcher LA, Sullivan JM et al. Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity 2011;35:986-96.
35. Mitsdoerffer M, Lee Y, Jäger A et al. Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc Natl Acad Sci U S A 2010;107:14292-7.
36. Nguyen CQ, Yin H, Lee BH et al. Pathogenic effect of interleukin-17A in induction of Sjögren's syndrome-like disease using adenovirus-mediated gene transfer. Arthritis Res Ther 2008;12:R220.
37. Ding Y, Li J, Wu Q et al. IL-17RA is essential for optimal localization of follicular Th cells in the germinal center light zone to promote autoantibody-producing B cells. J Immunol 2013;191:1614-24.
38. Seror R, Theander E, Brun JG et al. Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis 2015;74:859-66.
39. + cell and its subpopulations in primary Sjögren's syndrome. J Immunol Res 2015; 2015:307453.
40. Sudzius G, Mieliauskaite D, Butrimiene I et al. Activity of Thelper cells in patients with primary Sjögren's syndrome. In Vivo 2013;27:263-8.
41. Gonzalez Y, Herrera MT, Juárez E et al. CD161 expression defines a Th1/Th17 polyfunctional subset of resident memory T lymphocytes in bronchoalveolar cells. PloS One 2015;10:e0123591.
42. Samson M, Audia S, Fraszczak J et al. Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. Arthritis Rheum 2012;64:3788-98.
43. Afzali B, Mitchell PJ, Edozie FC et al. CD161 expression characterizes a subpopulation of human regulatory T cells that produces IL-17 in a STAT3-dependent manner. Eur J Immunol 2013;43:2043-54.
44. Nistala K, Adams S, Cambrook H et al. Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment. Proc Natl Acad Sci U S A 2010;107: 14751-6.
45. Roescher N, Tak PP, Illei GG. Cytokines in Sjögren's syndrome. Oral Dis 2009;15:519-26.
46. Kang EH, Lee YJ, Hyon JY et al. Salivary cytokine profiles in primary Sjögren's syndrome differ from those in non-Sjögren sicca in terms of TNF-α levels and Th-1/Th-2 ratios. Clin Exp Rheumatol 2011;29:970-6.
47. O'Keeffe J, Doherty DG, Kenna T et al. Diverse populations of T cells with NK cell receptors accumulate in the human intestine in health and in colorectal cancer. Eur J Immunol 2004;34:2110-9.